Schroder Investment Management Group Acquires 146,403 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Schroder Investment Management Group boosted its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 118.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 270,336 shares of the company's stock after acquiring an additional 146,403 shares during the period. Schroder Investment Management Group owned 0.40% of EyePoint Pharmaceuticals worth $1,898,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EYPT. Vanguard Group Inc. increased its position in shares of EyePoint Pharmaceuticals by 24.8% in the fourth quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company's stock worth $28,334,000 after purchasing an additional 755,045 shares during the period. Franklin Resources Inc. grew its stake in EyePoint Pharmaceuticals by 9.9% during the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock worth $32,056,000 after buying an additional 362,399 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in EyePoint Pharmaceuticals by 1,171.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock valued at $2,970,000 after buying an additional 342,516 shares during the period. abrdn plc acquired a new position in shares of EyePoint Pharmaceuticals in the 4th quarter valued at approximately $1,719,000. Finally, Barclays PLC lifted its holdings in shares of EyePoint Pharmaceuticals by 410.4% during the 3rd quarter. Barclays PLC now owns 245,045 shares of the company's stock worth $1,959,000 after acquiring an additional 197,033 shares during the period. 99.41% of the stock is owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Stock Up 12.1 %

Shares of EYPT stock traded up $0.58 during trading hours on Friday, hitting $5.38. 898,348 shares of the company's stock traded hands, compared to its average volume of 911,068. The stock has a market cap of $369.76 million, a PE ratio of -2.69 and a beta of 1.39. The stock's 50 day simple moving average is $6.04 and its 200 day simple moving average is $7.91. EyePoint Pharmaceuticals, Inc. has a 12 month low of $3.91 and a 12 month high of $23.65.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). The company had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. As a group, equities research analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. StockNews.com raised shares of EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. Chardan Capital reissued a "buy" rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. HC Wainwright reaffirmed a "buy" rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Finally, Citigroup started coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating and a $33.00 price objective for the company. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $26.63.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.